These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10430048)

  • 21. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
    Souza DG; Cassali GD; Poole S; Teixeira MM
    Br J Pharmacol; 2001 Nov; 134(5):985-94. PubMed ID: 11682446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors.
    Nakata A; Ogawa K; Sasaki T; Koyama N; Wada K; Kotera J; Kikkawa H; Omori K; Kaminuma O
    Clin Exp Immunol; 2002 Jun; 128(3):460-6. PubMed ID: 12067300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rolipram inhibits polarization and migration of human T lymphocytes.
    Layseca-Espinosa E; Baranda L; Alvarado-Sánchez B; Portales-Pérez D; Portillo-Salazar H; González-Amaro R
    J Invest Dermatol; 2003 Jul; 121(1):81-7. PubMed ID: 12839567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats.
    Sato T; Otaka M; Odashima M; Kato S; Jin M; Konishi N; Matsuhashi T; Watanabe S
    Biochem Biophys Res Commun; 2006 Jul; 346(1):339-44. PubMed ID: 16759642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent.
    Haskó G; Szabó C; Németh ZH; Salzman AL; Vizi ES
    Eur J Immunol; 1998 Feb; 28(2):468-72. PubMed ID: 9521054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors.
    Crocker IC; Ohia SE; Church MK; Townley RG
    J Allergy Clin Immunol; 1998 Nov; 102(5):797-804. PubMed ID: 9819297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
    Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
    J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes.
    Ekholm D; Mulloy JC; Gao G; Degerman E; Franchini G; Manganiello VC
    Biochem Pharmacol; 1999 Sep; 58(6):935-50. PubMed ID: 10509746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression.
    Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
    J Allergy Clin Immunol; 1997 Jan; 99(1 Pt 1):28-37. PubMed ID: 9003208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons.
    Yamashita N; Hayashi A; Baba J; Sawa A
    Jpn J Pharmacol; 1997 Oct; 75(2):155-9. PubMed ID: 9414030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity.
    Heystek HC; Thierry AC; Soulard P; Moulon C
    Int Immunol; 2003 Jul; 15(7):827-35. PubMed ID: 12807821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
    Au BT; Teixeira MM; Collins PD; Williams TJ
    Br J Pharmacol; 1998 Mar; 123(6):1260-6. PubMed ID: 9559913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells.
    Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
    Am J Respir Cell Mol Biol; 1995 Dec; 13(6):692-702. PubMed ID: 7576707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
    Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT.
    Navarro J; Punzón C; Jiménez JL; Fernández-Cruz E; Pizarro A; Fresno M; Muñoz-Fernández MA
    J Virol; 1998 Jun; 72(6):4712-20. PubMed ID: 9573235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.
    Martin-Chouly CA; Astier A; Jacob C; Pruniaux MP; Bertrand C; Lagente V
    Life Sci; 2004 Jul; 75(7):823-40. PubMed ID: 15183075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
    Yamamoto S; Sugahara S; Naito R; Ichikawa A; Ikeda K; Yamada T; Shimizu Y
    Eur J Pharmacol; 2006 Jul; 541(1-2):106-14. PubMed ID: 16780833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.